Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA4 | P43681 | 5/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.40 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.40 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 2/20 | 0.40 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.38 |
| ▸ | PDE2A | O00408 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3331013 | 0.93 | CHRNA4 (0.62) | CHRNA4MEN1KMT2AMBTD1L3MBTL3 | |
| SCHEMBL3336162 | 0.93 | CHRNA4 (0.68) | CHRNA4MEN1KMT2AHCAR2KDM1A | |
| SCHEMBL3330935 | 0.90 | CHRNA4 (0.62) | CHRNA4MEN1KMT2AHCAR2HCRTR1 | |
| SCHEMBL3333159 | 0.87 | CHRNA4 (0.64) | CHRNA4MEN1KMT2AMBTD1L3MBTL3 | |
| SCHEMBL3337547 | 0.85 | CHRNA4 (0.58) | CHRNA4MBTD1L3MBTL3PADI4 | |
| SCHEMBL3340669 | 0.85 | CHRNA4 (0.61) | CHRNA4MBTD1L3MBTL3PADI4HCRTR1 | |
| SCHEMBL3332357 | 0.83 | CHRNA4 (0.65) | CHRNA4MEN1KMT2AHCAR2PDE2A | |
| SCHEMBL3335904 | 0.81 | CHRNA4 (0.83) | CHRNA4MEN1KMT2A | |
| SCHEMBL3340908 | 0.81 | CHRNA4 (0.57) | CHRNA4KMT2AMBTD1L3MBTL3PADI4 | |
| SCHEMBL3340832 | 0.81 | CHRNA4 (0.74) | CHRNA4MEN1KMT2AHCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144700-A1 | HETEROCYCLIC-CARBONYL-DIAZABICYCLOALKANES AS MODULATORS OF THE NEURONAL NICOTINIC ACETYLCHOLINE ALPHA 4 BETA 2, SUBTYPE RECEPTOR FOR THE TREATMENT OF CNS RELATED DISORDERS | TARGACEPT, INC. (US) | 2010-06-10 | — | — | US | claimed |
| WO-2008112734-A1 | HETEROCYCLIC-CARBONYL-DIAZABICYCLOALKANES AS MODULATORS OF THE NEURONAL NICOTINIC ACETYLCHOLINE ALPHA 4 BETA 2, SUBTYPE RECEPTOR FOR THE TREATMENT OF CNS RELATED DISORDERS | TARGACEPT, INC. (US) | 2008-09-18 | — | — | WO | claimed |
| US-20100144700-A1 | HETEROCYCLIC-CARBONYL-DIAZABICYCLOALKANES AS MODULATORS OF THE NEURONAL NICOTINIC ACETYLCHOLINE ALPHA 4 BETA 2, SUBTYPE RECEPTOR FOR THE TREATMENT OF CNS RELATED DISORDERS | TARGACEPT, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| WO-2008112734-A1 | HETEROCYCLIC-CARBONYL-DIAZABICYCLOALKANES AS MODULATORS OF THE NEURONAL NICOTINIC ACETYLCHOLINE ALPHA 4 BETA 2, SUBTYPE RECEPTOR FOR THE TREATMENT OF CNS RELATED DISORDERS | TARGACEPT, INC. (US) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144700-A1 | HETEROCYCLIC-CARBONYL-DIAZABICYCLOALKANES AS MODULATORS OF THE NEURONAL NICOTINIC ACETYLCHOLINE ALPHA 4 BETA 2, SUBTYPE RECEPTOR FOR THE TREATMENT OF CNS RELATED DISORDERS | CHRNA10, CHRNA2, CHRNE | CHRNA4 8/4885MEN1 4055/4885KMT2A 2271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.